New $2.2 Quadrillion Trend About To Open Up
Massive Opportunities For Investors
Continue Reading
pixel

Vijay Iyengar Biography and Net Worth

EVP of Incyte


Vijay Iyengar joined Incyte in May 2016 as Executive Vice President, Global Strategy and Corporate Development leading the company’s Global Product Strategy, Business Development and Licensing, and Alliance Management teams. Dr. Iyengar has more than 13 years of pharmaceutical industry experience, most recently serving as the President of Genoptix Corporation, a Novartis Company. At Genoptix, he led a 650-person organization focused on delivering CAP/CLIA certified oncology diagnostic testing as well as providing clinical trial assay development and execution services. Previously, Dr. Iyengar held leadership roles in both U.S. and Global commercial functions at Novartis—he was Vice President and Rare Diseases Franchise Head at Novartis Oncology and Vice President and Oncology General Manager of Novartis Greece. Before joining Novartis in 2003, Dr. Iyengar was an Engagement Manager at McKinsey & Company where he served pharmaceutical and medical device clients as part of their healthcare practice. Dr. Iyengar received his Bachelor of Science degree in Biology from Stanford University and earned his MD from Harvard Medical School.

What is Vijay K. Iyengar's net worth?

The estimated net worth of Vijay K. Iyengar is at least $2.69 million as of July 7th, 2022. Dr. Iyengar owns 40,313 shares of Incyte stock worth more than $2,685,249 as of September 29th. This net worth estimate does not reflect any other assets that Dr. Iyengar may own. Learn More about Vijay K. Iyengar's net worth.

How do I contact Vijay K. Iyengar?

The corporate mailing address for Dr. Iyengar and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected] Learn More on Vijay K. Iyengar's contact information.

Has Vijay K. Iyengar been buying or selling shares of Incyte?

During the last ninety days, Vijay K. Iyengar has sold $459,372.06 in shares of Incyte stock. Most recently, Vijay K. Iyengar sold 5,787 shares of the business's stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $79.38, for a transaction totalling $459,372.06. Following the completion of the sale, the executive vice president now directly owns 40,313 shares of the company's stock, valued at $3,200,045.94. Learn More on Vijay K. Iyengar's trading history.

Who are Incyte's active insiders?

Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (President), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.

Are insiders buying or selling shares of Incyte?

During the last twelve months, Incyte insiders bought shares 6 times. They purchased a total of 2,137,539 shares worth more than $153,065,544.39. During the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 89,978 shares worth more than $6,074,106.53. The most recent insider tranaction occured on July, 22nd when insider Thomas Tray sold 1,564 shares worth more than $130,015.32. Insiders at Incyte own 17.5 % of the company. Learn More about insider trades at Incyte.

Information on this page was last updated on 7/22/2022.

Vijay K. Iyengar Insider Trading History at Incyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2022Sell5,787$79.38$459,372.0640,313View SEC Filing Icon  
7/29/2021Sell4,911$78.29$384,482.19View SEC Filing Icon  
7/9/2018Sell606$71.34$43,232.04View SEC Filing Icon  
1/2/2018Sell5,000$97.26$486,300.00View SEC Filing Icon  
See Full Table

Vijay K. Iyengar Buying and Selling Activity at Incyte

This chart shows Vijay K Iyengar's buying and selling at Incyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Incyte Company Overview

Incyte logo
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $66.61
Low: $66.14
High: $67.58

50 Day Range

MA: $72.48
Low: $66.18
High: $82.86

2 Week Range

Now: $66.61
Low: $61.91
High: $84.86

Volume

1,263,072 shs

Average Volume

1,525,384 shs

Market Capitalization

$14.82 billion

P/E Ratio

15.67

Dividend Yield

N/A

Beta

0.66
New $2.2 Quadrillion Trend About To Open Up
Massive Opportunities For Investors
Continue Reading
pixel